Absci(US:ABSI) Globenewswire·2025-10-15 12:00Core Insights - Absci is hosting a virtual seminar on December 11, 2025, to discuss its ABS-201 program for androgenetic alopecia, featuring leading KOLs in dermatology and hair loss [1][2] - The Phase 1/2a trial for ABS-201 is now expected to begin in early December 2025, ahead of previous guidance for early 2026, with interim efficacy results anticipated in the second half of 2026 [2][5] Company Overview - Absci is a clinical-stage biotech company focused on advancing therapeutics using generative AI, with a platform that integrates AI models and synthetic biology to create innovative biologics [6] - The company is developing ABS-201, a novel therapeutic targeting prolactin receptors to stimulate hair follicle regeneration, showing superior hair regrowth compared to minoxidil in preclinical studies [5][6] Market Context - Androgenetic alopecia affects approximately 80 million Americans, with current FDA-approved treatments like minoxidil and finasteride having limited efficacy and notable side effects [4] - ABS-201 aims to redefine treatment possibilities for androgenetic alopecia, addressing a significant unmet need in the market [5][6] Event Details - The webinar will feature presentations on the ABS-201 program's latest developments, followed by an interactive Q&A session, concluding around 12:00 p.m. ET [3] - Key opinion leaders presenting include Dr. David J. Goldberg, Dr. Ralf Paus, and Dr. Rodney Sinclair, among others [7]